Osimertinib Mesylate Tablets Clinical Trials
3 recruitingDrug
Phase 22Phase 31
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
NSCLC Patients With Brain Metastasis
Allist Pharmaceuticals, Inc.380 enrolled1 locationNCT06970639
Recruiting
Phase 2
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.40 enrolled1 locationNCT06498986
Recruiting
Phase 2
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.400 enrolled1 locationNCT06895928